Extend Biosciences is awarded a Phase II SBIR grant from NCI
Extend Biosciences was awarded a Phase II SBIR grant from the National Cancer Institute to fund efficacy and IND-enabling studies for a long-acting ghrelin molecule for cancer cachexia.
Extend Biosciences was awarded a Phase II SBIR grant from the National Cancer Institute to fund efficacy and IND-enabling studies for a long-acting ghrelin molecule for cancer cachexia.